RxDoctor Payments Data

Ammon Weber, MD

Family Medicine · Borger, TXNPI 1851499248

Payments from drug & device makers

$583in general payments, 2019–2025

Across 33 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$176
  • AbbVie$124
  • Takeda Pharmaceuticals U.S.A., Inc.$61
  • Lundbeck LLC$31
  • AstraZeneca$23
  • Supernus Pharmaceuticals, Inc.$21
  • plus $148 from 9 others

What the payments were for

  • Food & beverage$583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$583 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$9,249
Medicare patients
29
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$102,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$63,707
JardianceEmpagliflozin53$50,718
EliquisApixaban35$36,203
JanuviaSitagliptin Phosphate22$28,775
EntrestoSacubitril/Valsartan23$27,069
QuliptaAtogepant19$21,569
RybelsusSemaglutide15$21,172
TrulicityDulaglutide22$21,127
MounjaroTirzepatide16$17,073
Combivent RespimatIpratropium/Albuterol Sulfate19$15,593
TrintellixVortioxetine Hydrobromide13$12,602
LinzessLinaclotide17$12,314
Tresiba Flextouch U-200Insulin Degludec20$10,927
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen217$7,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$123,845112 claims
GSKTrelegy Ellipta$176$63,70770 claims
Lilly USA, LLCTrulicity, Mounjaro$18$38,20138 claims
AbbVieQulipta, Linzess, Synthroid$124$35,91959 claims
MerckJanuvia$12$28,77522 claims
NovartisEntresto$20$27,06923 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$61$12,60213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Borger

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →